Amlodipine and supplements: interactions, cautions, and safe stacks
Amlodipine's interaction profile is gentler than that of the non-dihydropyridine calcium channel blockers (diltiazem, verapamil) because amlodipine does not itself inhibit CYP3A4. Its very long half-life (30–50 hours) further blunts the impact of short-lived pharmacokinetic perturbations like a single glass of grapefruit juice. The clinically meaningful issues are concentrated in two areas: (1) potent CYP3A4 modulation (St John's wort, daily grapefruit, high-dose piperine) and (2) additive cardiovascular effects (hawthorn, CoQ10, high-dose calcium).
Avoid combiningAvoid
St John's wort is a strong CYP3A4 inducer. Co-administration can reduce amlodipine area-under-the-curve (AUC) by approximately 50%, with documented case reports of loss of blood-pressure control during chronic St John's wort use. The interaction onset is slow (1–2 weeks for full enzyme induction) and offset is similarly slow after discontinuation, so check blood pressure within 2 weeks of either starting or stopping. PMID 38025741
Caution / watch carefullyCaution
Grapefruit (whole fruit or juice) produces a modest 1.2–1.6× increase in amlodipine AUC with regular consumption. Occasional small servings are clinically inconsequential — this is not the catastrophic interaction grapefruit has with simvastatin. Daily heavy consumption is the relevant pattern to flag. PMID 11963641
Hawthorn berry has additive vasodilatory and mild calcium-channel-modulating activity. The most reliable real-world consequence is amplification of amlodipine-induced ankle oedema rather than dangerous hypotension. Patients already troubled by amlodipine oedema should not add hawthorn. PMID 38025741
Berberine mildly inhibits CYP3A4 and may raise amlodipine exposure at higher doses (>1500 mg/day). Clinical relevance is modest — monitor for new oedema or symptomatic hypotension on initiation. PMID 21168349
Piperine (the active extract in black pepper-derived "bioavailability enhancers" added to many curcumin and turmeric formulations) inhibits CYP3A4 and can raise amlodipine AUC. The effect is modest at culinary intake but meaningful at supplemental doses (5–20 mg piperine added to curcumin products). PMID 23792203
Watch (mild signals)Watch
High-dose oral calcium (>1000 mg/day) can theoretically blunt amlodipine efficacy by repleting intracellular calcium stores, although clinical evidence of this effect with amlodipine specifically is limited and the magnitude appears small. Patients on bone-protection regimens generally do not need to change calcium dosing. Manufacturer label
CoQ10 at 100–200 mg/day has a mild additive blood-pressure-lowering effect — usually a positive interaction, occasionally a reason for transient symptomatic hypotension at initiation. Useful adjunct in patients with statin co-therapy or in heart-failure protocols. PMID 25933483
Often supportive / no problematic interactionSafe
Magnesium is well-tolerated with amlodipine and may produce a modest additive antihypertensive benefit. There is no pharmacokinetic interaction. Magnesium glycinate or citrate at 200–400 mg elemental magnesium per day is a reasonable adjunct in hypertensive patients with documented or likely insufficient intake. PMID 27402922
Mechanism — why these supplements matter for amlodipine
Amlodipine is metabolised principally by CYP3A4. Unlike diltiazem and verapamil, it does not itself inhibit CYP3A4 — so the directionality of interactions runs almost entirely into amlodipine rather than out of it. The four mechanistic categories worth knowing are:
- CYP3A4 inducers (St John's wort) — reduce amlodipine exposure; blood-pressure rebound and loss of control.
- CYP3A4 inhibitors (grapefruit, berberine, piperine) — raise amlodipine exposure; usually small magnitude, occasionally enough to amplify oedema or symptomatic hypotension.
- Pharmacodynamic additives (hawthorn, CoQ10, magnesium) — directly add to BP lowering or vasodilation; usually benign but worth flagging.
- Absorption competition (high-dose oral calcium) — theoretical, small clinical effect.
The very long half-life of amlodipine (30–50 hours) means that any of these interactions take days to fully manifest. A blood-pressure check within 1–2 weeks of starting or stopping any item on this page is the simplest objective monitor.
What to do if you're already taking amlodipine and any of these
The single most important step is to tell your prescriber what supplements you take. Most amlodipine interactions are manageable, but they are not all manageable in the same way — St John's wort needs to come off; daily heavy grapefruit can be moderated; hawthorn-related oedema is a stop-this discussion; CoQ10 and magnesium are usually fine to continue.
If you take any of the Caution-tier supplements and notice new ankle oedema, dizziness on standing, unusual fatigue, or a change in your usual blood-pressure readings, that is the trigger for a same-week conversation rather than a "discuss at next appointment" item.
Related class context
Amlodipine sits in a broader class with very different interaction profiles. The non-dihydropyridine CCBs (diltiazem, verapamil) inhibit CYP3A4 themselves, which is why they push other drugs (digoxin, certain statins) into toxicity — amlodipine does not do this. Felodipine and nifedipine have stronger grapefruit interactions (~3× AUC for felodipine versus 1.2–1.6× for amlodipine). For the full picture of how amlodipine compares to the rest of the CCB family, see the calcium channel blocker class page.
Sources
- Pfizer. Norvasc (amlodipine besylate) prescribing information. US FDA label, accessed 2026-05. (Class-default CYP3A4 metabolism and interaction profile.)
- Vaclavik J, et al. Amlodipine and St John's wort: clinically relevant CYP3A4 induction reducing antihypertensive efficacy. Review. PMID: 38025741.
- Vincent J, et al. Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. PMID: 11963641.
- Guo Y, et al. Berberine and CYP3A4-mediated drug interactions: a systematic review. PMID: 21168349.
- Bhardwaj RK, et al. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. PMID: 23792203.
- Rosenfeldt FL, et al. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. PMID: 25933483.
- Zhang X, et al. Effects of magnesium supplementation on blood pressure: a meta-analysis of randomized double-blind placebo-controlled trials. PMID: 27402922.
Educational reference, not medical advice. Drug interaction profiles change with new evidence. Confirm any supplement change with your prescriber or pharmacist before acting on this page.